Floatz logo

Raltegravir

Liver Failure

ANRS, Emerging Infectious DiseasesSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Liver Failure cohort.

Asset / SponsorPhaseRating
Empagliflozin
Yale University
Phase 4BB
Avatrombopag
Tongji Hospital
Phase 4BB
Erythropoietin Human Recombinant
Institute of Liver and Biliary Sciences, India
Phase 3BB
Pentoxifylline
Assistance Publique - Hôpitaux de Paris
Phase 3BB
SODIUM TETRADECYL SULFATE
Kaohsiung Veterans General Hospital.
Phase 3B

View all 24 →

Same molecule, other indications

Raltegravir is also rated in:

HIV infectious diseaseDormant
A
Indicative ·
80 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
68 / 100
View asset →
osteoporosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →